Last reviewed · How we verify

NCT06224777

Comparison of Fluid Resuscitation in Pediatric Burn Patients Using Crystalloids and With Albumin on Day Two.

Completed Phase 2, PHASE3 Last updated 25 January 2024
What this trial tests

Phase 2, PHASE3 trial testing 5% Albumin (human) Solution in Burns in 90 participants. Completed in 17 May 2023.

Timeline
1 January 2022
Primary endpoint
18 December 2022
17 May 2023

Quick facts

Lead sponsorKing Edward Medical University
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment90
Start date1 January 2022
Primary completion18 December 2022
Estimated completion17 May 2023
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

King Edward Medical University

Who can join

Adults 1 to 12, any sex, with Burns. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this comparative, interventional randomized controlled trial is to use albumin during resuscitation in pediatric burn patients on day 2, as it can reduce extravasation of fluids and decrease the overall fluid requirements, along with mortality and maintain circulation. Participants will be divided into 2 groups. Albumin will be administered additionally in group A, while only crystalloids will be used for resuscitation in group B.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Burns

Currently open trials in the same condition.

Other King Edward Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06224777.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing